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Methicillin-resistant  Staphylococcus aureus (MRSA) 
has become a pathogen of animals. To compare types of 
infections, clinical outcomes, and risk factors associated 
with MRSA in dogs with those associated with methicillin-
susceptible Staphylococcus aureus (MSSA) infections, we 
conducted a case–control study at 3 veterinary referral hos-
pitals in the United States and Canada during 2001–2007. 
Risk factors analyzed were signalment, medical and surgi-
cal history, and infection site. Among 40 dogs with MRSA 
and 80 with MSSA infections, highest prevalence of both in-
fections was found in skin and ears. Although most (92.3%) 
dogs with MRSA infections were discharged from the hospi-
tal, we found that signiﬁ  cant risk factors for MRSA infection 
were receipt of antimicrobial drugs (odds ratio [OR] 3.84, p 
= 0.02), β-lactams (OR 3.58, p = 0.04), or ﬂ  uoroquinolones 
(OR 5.34, p = 0.01), and intravenous catheterization (OR 
3.72, p = 0.02). Prudent use of antimicrobial drugs in veteri-
nary hospitals is advised.
D
uring the past 2 decades, methicillin-resistant Staphy-
lococcus aureus (MRSA) has gained global atten-
tion as a human pathogen in hospitals and in communi-
ties. Recent reports of MRSA infection and colonization 
of dogs and cats (1–5) indicate that MRSA has apparently 
emerged as a pathogen of animals as well. Most reported 
MRSA infections in dogs have involved wound and post-
operative infections (2), but evaluation is lacking regard-
ing speciﬁ  c types of infections, clinical outcomes, and risk 
factors associated with such MRSA infections in dogs. No 
current evidence points to whether MRSA infections, in 
terms of location of infection, severity of disease, or clini-
cal outcome, differ from methicillin-susceptible S. aureus 
(MSSA) infections.
The literature about human medicine has compared 
MRSA-infection risk factors (6,7), mortality rates (6,8–10), 
and clinical features (6) with those for MSSA infections. 
Results from a meta-analysis of 31 cohort studies showed 
that for patients with MRSA bacteremia, mortality rates 
were signiﬁ  cantly higher than for patients with MSSA bac-
teremia (11). This mortality rate difference between MRSA 
and MSSA infections might result from treatment with in-
appropriate antimicrobial drugs or the restricted number of 
antimicrobial drugs available for treatment (12). With re-
spect to animals, however, limited data are available; only 
1 study has evaluated these MRSA and MSSA infections. 
Morris et al. (13) compared MRSA and MSSA infections 
in cats but were unable to detect signiﬁ  cant differences in 
signalment, clinical presentations, or outcomes. Two other 
studies have reported potential risk factors associated with 
MRSA colonization in horses admitted to a veterinary re-
ferral hospital (14,15). Accurate data are needed to iden-
tify the differences between MRSA and MSSA infections 
in dogs as well as the clinical relevance of MRSA beyond 
concerns associated with antimicrobial drug resistance. To 
gain those data, epidemiologic research is required. Re-
search is also required for proper medical treatment of dogs 
with MRSA infections, for counseling of clients of infected 
animals, and for elucidation of possible reasons for the 
emergence of MRSA in pets. Our study objectives were to 
compare the types of infections, clinical outcomes, and risk 
factors for MRSA and MSSA infections in dogs.
Materials and Methods
Selection of Case-Patients and Controls
From 2001 through 2007, we conducted a retrospec-
tive, secondary-base, case–control study at 3 veterinary re-
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ferral hospitals: the Ontario Veterinary College Veterinary 
Teaching Hospital (Guelph, Ontario, Canada), Matthew J. 
Ryan Veterinary Hospital of the University of Pennsylva-
nia (Philadelphia, PA, USA), and Angell Animal Medical 
Center (Boston, MA, USA). These hospitals offer a variety 
of small animal medical specialties and services. Each year 
they receive ≈14,000, 30,000, and 50,000 patients, respec-
tively. Each hospital used its microbiology database to iden-
tify MRSA and MSSA infections in dogs. Each dog with an 
identiﬁ  ed MRSA infection (case-patient) was matched—by 
veterinary referral hospital and by date of admission—to 2 
control dogs with MSSA (the dogs seen immediately before 
and after the dog with MRSA). Dogs merely colonized by 
MRSA or MSSA were excluded from analysis.
Data Collection
To collect information, we used medical records of all 
case-patient and control dogs to answer a pretested, stan-
dardized questionnaire. Data were collected on signalment, 
medical and surgical history, infection, hospital duration, 
and clinical outcome. Signalment data included breed, age, 
and sex. Medical and surgical history was limited to a 90-
day period before admission to the referral hospital and 
included antimicrobial drug treatment, hospitalization, and 
surgical procedure. MRSA or MSSA infection data com-
prised site of infection and procedures performed before 
onset of infection, such as surgery, endoscopy, colonos-
copy, intravenous catheterization, and urinary catheteriza-
tion. Clinical outcome data covered whether surgery was 
required because of the infection and whether the animal 
was discharged, was euthanized, or died.
Because of a large number of categories, we recatego-
rized several variables. Breed was categorized according 
to size based on weight: small (1–10 kg), medium (>10–25 
kg), or large (>25 kg). Age was categorized as young (<2 
years), middle aged (>2–8 years), or old (>8 years). Site 
(where MRSA or MSSA was cultured) was categorized as 
skin, ear, urinary, skeletal, and other (abdominal ﬂ  uid, tho-
racic ﬂ  uid, blood, oral cavity, lymph node, vagina, transtra-
cheal wash ﬂ  uid, and milk). The number of days dogs were 
hospitalized was categorized as short (<2 days), medium 
(3–7 days), or long (>7 days). Finally, speciﬁ  c antimicro-
bial drugs were grouped according to classes, i.e., amino-
glycoside,  β-lactam, chloramphenicol, ﬂ  uoroquinolone, 
lincosamide, nitroimidazole, and tetracycline. For analyti-
cal purposes, dogs were subcategorized into 4 groups: did 
not receive any antimicrobial drug in the previous 90 days, 
received that speciﬁ  c class of antimicrobial drug, received 
another class of antimicrobial drug, and unknown status.
Statistical Analyses
All descriptive statistics, model building, and analyses 
were performed by using Stata 10.0 (StataCorp, College 
Station, TX, USA) and by using exact logistic regression. 
In Stata, the score method was used for calculating p values, 
and the group option was applied to account for matching 
(16). All tests were 2 sided, and signiﬁ  cance was based on 
p<0.05. For predictor variables, odds ratios (ORs) and 95% 
conﬁ  dence intervals (CIs) were calculated. For descriptive 
variables listed in the categories of signalment, medical and 
surgical history, and infection, the outcome was deﬁ  ned as 
having MRSA or MSSA infection. Variables in the clinical 
outcome category were modeled as dependent variables, 
and MRSA or MSSA infection was the independent vari-
able. To avoid problems associated with colinearity, we 
performed a correlation analysis to identify pairs of predic-
tor variables that had high colinearity (|r|>0.8). We did not 
construct a multivariable model because of the relatively 
small sample size, resultant concerns of stability, and prob-
lems associated with overﬁ  tting. Consequently, we con-
structed only univariable models.
Results
A total of 40 MRSA case-patients and 80 MSSA con-
trols were eligible for inclusion. From each hospital, the 
number of case-patients and controls were, respectively, 7 
and 14 (Ontario Veterinary College), 20 and 40 (Matthew 
J. Ryan Veterinary Hospital), and 13 and 26 (Angell Ani-
mal Medical Center).
Breed distribution was categorized according to weight 
(Table 1). Ages of MRSA case-patients ranged from 1 to 
13 years (mean 5.6 and median 5.0 years). Ages of MSSA 
control dogs ranged from 6 months to 16 years (mean 6.8 
and median 7.0 years). No distinction was made between 
intact or sterilized dogs. Overall, no signiﬁ  cant differences 
appeared between case-patients and controls with respect 
to breed (p = 0.18), age (p = 0.50), or sex (p = 0.29).
Regarding previous hospitalization or surgical proce-
dures, no overall signiﬁ  cant differences appeared between 
the MRSA and MSSA groups (p = 0.62 and 0.40, respec-
tively). Results from the univariable analysis (Table 2) in-
dicate that receipt of antimicrobial drugs (OR 3.84, 95% CI 
1.21–14.74, p = 0.02), β-lactams (OR 3.58, 95% CI 1.04–
14.79, p = 0.04), or ﬂ  uoroquinolones (OR 4.61, 95% CI 
1.08–27.37, p = 0.02), within 90 days before admission was 
signiﬁ  cantly associated with a MRSA infection. Further-
more, when ﬂ  uoroquinolones and β-lactams were included 
in the “other classes” category, the odds of a dog having 
MRSA versus MSSA infection increased over odds for 
dogs that had not received antimicrobial drugs (Table 2).
Most MRSA and MSSA infections were located on the 
skin. Overall, with regard to infection site, we found no sig-
niﬁ  cant difference between the MRSA and MSSA groups 
(p = 0.50) (Table 3). Before onset of the MRSA and MSSA 
infections, the most common procedure was intravenous 
catheterization—a signiﬁ  cant risk factor for a MRSA in-
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fection (OR 3.27, 95% CI 1.14–10.65, p = 0.02). Neither 
colonoscopy nor endoscopy was performed on any animal. 
Dogs with MRSA infection were hospitalized 0–29 days 
(mean 3.4 and median 1.5 days), whereas dogs with MSSA 
infection were hospitalized 0–13 days (mean 2.0 and medi-
an 0 days). Overall, in terms of duration of hospitalization, 
we found no signiﬁ  cant difference between case-patients 
and controls (p = 0.49).
Surgery was required for treatment of 16 (40.0%) of 40 
dogs with MRSA infection and 34 (42.5%) of 80 dogs with 
MSSA infection. Most dogs with MRSA and MSSA infec-
tions were discharged from the hospital (Table 4). For all 
dogs in the MRSA and MSSA groups that were euthanized, 
the infection was reported as the attributed cause of death. 
Overall, no signiﬁ   cant differences were noted between 
case-patients and controls with regard to surgery (p = 0.79) 
or outcome (p = 0.64).
Discussion
The identiﬁ  cation of receipt of antimicrobial drugs—
speciﬁ  cally β-lactams and ﬂ  uoroquinolones—as risk fac-
tors for a MRSA infection was not unexpected. Data from 
human medicine and a logical hypothesis each indicate that 
antimicrobial drug use in animals would increase the likeli-
hood of selection for multidrug-resistant bacteria such as 
MRSA. The case and control dogs included in this study 
were from veterinary referral hospitals; that is, tertiary care 
facilities that manage complicated medical and surgical 
cases referred from other veterinary facilities where treat-
ment, surgery, or both might have been initiated. This study 
identiﬁ  ed the highest prevalence of MRSA and MSSA in-
fections from the skin (pyoderma) and ears (otitis), which 
in dogs are frequently treated with β-lactams and ﬂ  uoro-
quinolones, respectively (17). Moreover, these conditions 
can become chronic and can result in repeated or prolonged 
antimicrobial drug treatments that might select for the de-
velopment of antimicrobial drug resistance (18). Before ad-
mission to the referral hospitals, >50% of dogs with MRSA 
infection were given antimicrobial drugs from the β-lactam 
family. Methicillin resistance in staphylococci involves 
the mecA gene, which encodes for the penicillin-binding 
protein 2a and results in reduced afﬁ  nity for all β-lactam 
antimicrobial drugs. Thus, medical management of MRSA 
cases can become complicated and can result in the admin-
istration of various classes of antimicrobial drugs (some of 
which can be ineffective), especially when culture and sus-
ceptibility testing have not been conducted.
In small animal medicine, ﬂ  uoroquinolones are com-
monly used because of their activity against a wide range of 
bacteria and their ability to be given orally (19). In humans, 
administration of antimicrobial drugs, including macrolides 
(7), β-lactams (20), and ﬂ  uoroquinolones (7,21), has been 
associated with increased risk for development of nosoco-
mial MRSA infections compared with nosocomial MSSA 
infections. Speciﬁ  cally, use of ﬂ  uoroquinolones has been 
positively correlated with the incidence of hospital-associ-
ated MRSA (22) infections. In addition to the direct effect 
of antimicrobial drugs on selection for antimicrobial drug–
resistant organisms, other mechanisms could facilitate 
emergence of MRSA during ﬂ  uoroquinolone  treatment. 
Research performed by Bisognano et al. (23) demonstrated 
that ﬂ  uoroquinolone-resistant MRSA and MSSA isolates 
exposed to subinhibitory levels of ciproﬂ  oxacin resulted in 
increased production of binding proteins, leading to higher 
levels of bacterial attachment. Thus, exposure to ﬂ  uoroqui-
nolones might promote the attachment of S. aureus while 
eradicating MSSA strains and might therefore promote ac-
quisition of MRSA strains (24).
In our study, information pertaining to antimicrobial 
drug exposure in the 90 days before admission to the vet-
erinary referral hospital was selected because that period 
was sufﬁ  cient for adequate review of medical charts. In 
the literature, periods for antimicrobial drug exposure as 
a risk factor for MRSA acquisition have ranged from 1 to 
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Table 1. Univariable analysis of demographic (signalment) risk factors for MRSA versus MSSA infections in dogs, United States and
Canada, 2001–2007* 
Variable MRSA, no. (%) dogs, n = 40  MSSA, no. (%) dogs, n = 80†  Odds ratio (95% CI)  p value‡ 
Breed, kg 
  Small, 1–10  10 (25)  11/79 (13.9)  Ref
  Medium, >10–25  16 (40)  28/79 (35.4)  0.63 (0.19–2.01)  0.43
  Large, >25  14 (35)  40/79 (50.6)  0.39 (0.12–1.25)  0.10
Age group, y
 <2 10 (25)  13 (16.3)  Ref
  3–8  20 (50)  43 (53.8)  0.63 (0.22–1.78)  0.34
  >8   10 (25)  24 (30)  0.54 (0.15–1.91)  0.39
Sex 
  F  14 (35)  36 (45)  Ref
  M  26 (65)  44 (55)  1.47 (0.65–3.45)  0.35
*MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; CI, confidence interval; Ref, referent 
category. Dogs with MRSA (case-patients) and MSSA (controls) infections were matched for veterinary referral hospital and date of admission.  
†Except as indicated. 
‡Score method for estimating p values does not assume a symmetrical distribution for discrete data. p<0.05 was considered significant. RESEARCH
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Table 2. Univariable analysis of medical and surgical risk factors for MRSA versus MSSA infections in dogs, United States and 
Canada, 2001–2007* 
Variable† MRSA, no. (%) dogs, n = 40 MSSA, no. (%) dogs,  n = 80 Odds ratio (95% CI)  p value‡ 
Received antimicrobial drugs 
  No  8 (20.0)  30 (37.5)  Ref
  Yes  26 (65.0)  33 (41.3)  3.84 (1.21–14.74)  0.02
  Don’t know  6 (15.0)  17 (21.2)  1.29 (0.28–5.65)  0.75
Received >2 antimicrobial drugs 
  No  25 (62.5)  56 (70.0)  Ref
  Yes  9 (22.5)  7 (8.8)  2.87 (0.81–11.49)  0.08
  Don’t know  6 (15.0)  17 (21.2)  0.79 (0.19–2.79)  0.78
Received an aminoglycoside
  No  8 (20.0)  30 (37.5)  Ref
  Yes  1 (2.5)  1 (1.3)  5.71 (0.06–517.45)  0.30
  Other classes§  25 (62.5)  32 (40.0)  3.80 (1.19–14.62)  0.02
  Don’t know  6 (15.0)  17 (21.2)  1.29 (0.28–5.62)  0.75
Received a ȕ-lactam 
  No  8 (20.0)  30 (37.5)  Ref
  Yes  18 (45.0)  25 (31.3)  3.58 (1.04–14.79)  0.04
  Other classes  8 (20.0)  8 (10.0)  4.18 (0.96–20.88)  0.04
  Don’t know  6 (15.0)  17 (21.2)  1.31 (0.28–5.69)  0.75
Received chloramphenicol 
  No  8 (20.0)  30 (37.5)  Ref
  Yes  1 (2.5)  2 (2.5)  2.61 (0.04–65.5)  1.00
  Other classes  25 (62.5)  31 (38.8)  3.84 (1.21–14.74)  0.02
  Don’t know  6 (15)  17 (21.2)  1.29 (0.28–5.65)  0.75
Received a fluoroquinolone 
  No  8 (20.0)  30 (37.5)  Ref
  Yes  9 (22.5)  7 (8.8)  5.34 (1.24–27.38)  0.01
  Other classes  17 (42.5)  26 (32.5)  3.24 (0.94–13.2)  0.06
  Don’t know  6 (15.0)  17 (21.2)  1.31 (0.29–5.74)  0.75
Received a lincosamide 
  No  8 (20.0)  30 (37.5)  Ref
  Yes  2 (5.0)  2 (2.5)  4.43 (0.27–75.86)  0.19
  Other classes  24 (60.0)  31 (38.8)  3.77 (1.18–14.53)  0.02
  Don’t know  6 (15.0)  17 (21.2)  1.32 (0.29–5.73)  0.75
Received a nitroimidazole 
  No  8 (20.0)  30 (37.5)  Ref
 Yes  2  (5.0)  0 7.18 (0.53–f) 0.07
  Other classes  24 (60.0)  33 (41.3)  3.47 (1.08–13.33)  0.03
  Don’t know  6 (15.0)  17 (21.2)  1.38 (0.29–6.17)  0.74
Received a tetracycline 
  No  8 (20.0)  30 (37.5)  Ref
  Yes  2 (5.0)  1 (1.3)  6.63 (0.29–463.75)  0.17
  Other classes  24 (60.0)  32 (40.0)  3.54 (1.11–13.65)  0.03
  Don’t know  6 (15.0)  17 (21.2)  1.33 (0.29–5.88)  0.74
Hospitalized
  No  16 (40.0)  38 (47.5)  Ref
  Yes  16 (40.0)  25 (31.3)  1.54 (0.58–4.14)  0.37
  Don’t know  8 (20.0)  17 (21.3)  1.17 (0.32–4.06)  0.08
Underwent surgical procedure 
  No  25 (62.5)  46 (57.5)  Ref
  Yes  10 (25.0)  16 (20.0)  1.07 (0.39–2.83)  1.00
  Don’t know  5 (12.5)  18 (22.5)  0.45 (0.09–1.68)  0.26
*MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; CI, confidence interval; Ref, referent 
category. Dogs with MRSA (case-patients) and MSSA (controls) infections were matched for veterinary referral hospital and date of admission.  
†Information obtained refers to the 90 days before admission to the veterinary referral hospital. 
‡Score method for estimating p values does not assume a symmetrical distribution for discrete data. p<0.05 was considered significant. 
§Refers to dogs given antimicrobial drugs from other drug classes. 
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12 months (25). Future studies with larger datasets might 
investigate the effect of varying time frames with respect to 
antimicrobial drug administration.
In dogs, identiﬁ  cation of intravenous catheterization as 
a risk factor for MRSA infection was not unexpected. Intra-
venous catheterization has been associated with increased 
rates of MRSA infections in humans (26) and has been sig-
niﬁ  cantly associated with death of horses with MRSA in-
fections (27). In previous studies as well as ours, however, 
intravenous catheterization might reﬂ  ect a consequence of 
MRSA infection rather than a risk factor for development 
of MRSA infection.
Overall and with respect to outcome (discharged vs. 
euthanized), no signiﬁ  cant differences between MRSA 
and MSSA infections were found. This ﬁ  nding is rel-
evant for counseling clients, particularly considering 
the publicity regarding MRSA and the possible percep-
tion that MRSA infections are untreatable or carry a poor 
prognosis. Numerous studies in human medicine have 
compared mortality rates associated with MRSA and 
MSSA infections, but the results have been conﬂ  icting 
(6,8,10,11). Wang et al. (6) were unable to detect an as-
sociation between higher mortality rates in patients with 
community-associated MRSA infections than in those 
with community-associated MSSA  infections. Melzer et 
al. (10) were unable to demonstrate that mortality rates for 
patients with hospital-associated MRSA infections were 
signiﬁ  cantly higher than those for patients with hospital-
associated MSSA infections. Conversely, results from a 
retrospective cohort study conducted by Wang et al. (8), 
indicated that the mortality rate for patients with hospital-
associated MRSA bacteremia was 1.78× higher than that 
for hospital-associated MSSA bacteremia. 
In our study, inadequate epidemiologic deﬁ  nitions and 
veterinary surveillance data prevented us from classifying 
MRSA and MSSA infections as hospital or community as-
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Table 3. Univariable analysis of infection site, duration of hospitalization, and medical and surgical risk factors for MRSA versus MSSA 
infections in dogs, United States and Canada, 2001–2007* 
Variable MRSA, no. (%) dogs, n = 40 MSSA, no. (%) dogs,  n = 80† Odds ratio (95% CI) p value‡
Site of infection 
  Skin  19 (47.5)  38/78 (48.7)  Ref
  Ear  5 (12.5)  11/78 (14.1)  0.89 (0.21–3.28)  1.00
  Skeletal§  7 (17.5)  6/78 (7.7)  2.69 (0.53–17.96)  0.23
  Urinary¶  3 (7.5)  11/78 (14.1)  0.37 (0.03–2.20)  0.29
  Other#  6 (15.0)  12/78 (15.4)  1.06 (0.24–4.14)  1.00
Duration of hospitalization 
 Short  (<2 d)  25 (62.5)  57 (71.3)  Ref
  Medium (3–7 d)  11 (27.5)  19 (23.8)  1.59 (0.52–4.94)  0.45
  Long (>7 d)  4 (10.0)  4 (5.0)  2.70 (0.43–17.49)  0.23
Intravenous catheterization** 
  No  21 (52.5)  58 (72.5)  Ref
  Yes  19 (47.5)  22 (27.5)  3.27 (1.14–10.65)  0.02
Surgery** 
  No  25 (62.5)  58 (72.5)  Ref
  Yes  15 (37.5)  22 (27.5)  1.61 (0.65–4.09)  0.29
Urinary catheterization** 
  No  36 (90.0)  77 (96.3)  Ref
  Yes  4 (10.0)  3 (3.8)  6.00 (0.48–314.98)  0.11
*MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; CI, confidence interval; Ref, referent 
category. Dogs with MRSA (case-patients) and MSSA (controls) infections were matched for veterinary referral hospital and date of admission. 
†Except as indicated. 
‡Score method for estimating p values does not assume a symmetrical distribution for discrete data. p<0.05 was considered significant. 
§Specimens were from internal joint surface, joint fluid, intramedullary pin, and orthopedic implant. 
¶Specimens were urine, urinary calculus, urinary catheter, and the wall of the urinary bladder. 
#Specimens were abdominal and thoracic fluids, blood, oral cavity swabs, lymph nodes, vaginal swabs, transtracheal wash fluid, and milk. 
**Procedures performed before infection occurred. 
Table 4. Clinical outcome characteristics for dogs with MRSA and MSSA infections, United States and Canada, 2001–2007* 
Variable MRSA, no. (%) dogs, n = 40 MSSA, no. (%) dogs,  n = 80†  Odds ratio (95% CI)  p value 
Surgery required because of infection 
   No  24 (60)  46 (57.5)  Ref
   Yes  16 (40)  34 (42.5)  0.89 (0.37–2.12)  0.84
Outcome
   Discharged  36/39 (92.3)  69/77 (89.6)  Ref
   Euthanized  3/39 (7.7)  8/77 (10.4)  0.63 (0.06–4.10)  0.71
*MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; CI, confidence interval; Ref, referent 
category. Dogs with MRSA (case-patients) and MSSA (controls) infections were matched for veterinary referral hospital and date of admission. RESEARCH
sociated. Nevertheless, other possible explanations as to 
why mortality rates between case-patients and controls did 
not differ signiﬁ  cantly might in part be the predominant 
infection types and the retrospective aspect of the study. 
Most MRSA and MSSA infections were pyodermas and 
otitis externa or interna infections, which are superﬁ  cial, 
rarely become invasive, and seldom result in death. Conse-
quently, infection types for which death would be a more 
realistic possible outcome were limited, resulting in a cor-
responding limitation in statistical power. Comparison of 
mortality rates between patients with MRSA or MSSA in-
fections would be best performed among only those with 
invasive infections and should be considered for future 
studies. Here, mortality rate information was obtained ret-
rospectively and only recorded up to the time of discharge. 
Thus, whether dogs died from their infections after dis-
charge from the referral hospital, causing an underestimate 
of deaths, is unknown.
Although our study was larger than previous studies, 
the power was still limited despite enrollment of 2 MSSA 
controls per each MRSA case-patient. Additional limita-
tions were enrollment of case-patients and controls from 
referral hospitals and the use of matching. Because dogs 
in this study were from referral hospitals, extrapolation of 
results to the general dog population might be biased. In 
general veterinary practice, antimicrobial drug use, hospi-
talization, surgical procedures, and speciﬁ  c medical and 
surgical cases might differ considerably from those in re-
ferral hospitals. The incomplete medical records that ac-
companied case-patients and controls from referral hospi-
tals might have affected responses to questions regarding 
previous medical or surgical procedures and antimicrobial 
drug use, all of which might have affected the results. Other 
potential risk factors such as underlying illnesses, admit-
ting service, hospitalization locations (i.e., intensive care 
unit vs. hospitalization ward), and treatment cost were not 
investigated but could play a role in the development and 
outcome of MRSA infections in dogs. Finally, by using 
matching to control for potential confounders, the matched 
factors—date of admission and referral hospital—preclud-
ed the investigation of these variables as potential risk fac-
tors for a MRSA infection.
Despite these limitations, however, we found no iden-
tiﬁ  able differences between MRSA and MSSA infections 
in dogs with regard to signalment, types of infections, and 
clinical outcome. The prognosis for a dog with a MRSA 
infection is reasonably good. However, when determining 
that prognosis and when counseling owners, veterinarians 
should focus on the location and severity of infection rather 
than the bacterium involved. Furthermore, administration 
of β-lactams and ﬂ  uoroquinolones were signiﬁ  cant risk fac-
tors for the development of a MRSA infection. This ﬁ  nding 
strengthens the need for veterinarians to consider prudent 
antimicrobial drug–use guidelines and to restrict the use of 
ﬂ  uoroquinolones as empirical or ﬁ  rst-line therapy. Guide-
lines should recommend identiﬁ  cation and susceptibility of 
the causal bacterial pathogen by performing a culture and 
susceptibility test. On the basis of susceptibility results, an-
timicrobial drugs should be dispensed at the proper dosage 
and duration for treatment and, in the absence of clinical 
disease, should not be prescribed.
Although only 4 risk factors were identiﬁ  ed as being 
signiﬁ  cantly associated with MRSA infection, results from 
the univariable analyses isolated several risk factors that 
have considerably large odds ratios or p values slightly 
greater than 0.05. With the exception of ﬂ  uoroquinolones 
and β-lactams, measure of association for all other antimi-
crobial drug classes was reasonably higher for those dogs 
given speciﬁ  c antimicrobial drugs compared with those 
that were not. Because of the small sample size, however, 
the power of these associations was limited.
Our study shows that MRSA is an emerging pathogen 
in dogs, and risk factors for MRSA infection are similar to 
those identiﬁ  ed in humans. Results from larger studies in 
the future might indicate that other classes of antimicrobial 
drugs, previous hospitalization and surgery, age, and the 
presence of a urinary catheter are also signiﬁ  cantly associ-
ated with MRSA infections. Only larger sample sizes will 
provide more information on MRSA and MSSA infections 
and will determine more accurately other risk factors as-
sociated with MRSA infections in dogs.
Dr Faires is a veterinarian and a PhD student in the Depart-
ment of Population Medicine at the Ontario Veterinary College, 
University of Guelph. Her primary research interests include the 
epidemiology of MRSA in people and animals.
References  
    1.   Walther B, Wieler LH, Friedrich AW, Hanssen AM, Kohn B, 
Brunnberg L, et al. Methicillin-resistant Staphylococcus aureus 
(MRSA) isolated from small and exotic animals at a university hos-
pital during routine microbiological examinations. Vet Microbiol. 
2008;127:171–8. DOI: 10.1016/j.vetmic.2007.07.018
    2.   Rich M, Roberts L. MRSA in companion animals. Vet Rec. 
2006;159:535–6.
  3.   Weese JS, Dick H, Willey BM, McGeer A, Kreiswirth BN, Innis B, 
et al. Suspected transmission of methicillin-resistant Staphylococcus 
aureus between domestic pets and humans in veterinary clinics and 
in the household. Vet Microbiol. 2006;115:148–55. DOI: 10.1016/j.
vetmic.2006.01.004
  4.   O’Mahony R, Abbott Y, Leonard FC, Markey BK, Quinn PJ, Pol-
lock PJ, et al. Methicillin-resistant Staphylococcus aureus (MRSA) 
isolated from animals and veterinary personnel in Ireland. Vet Mi-
crobiol. 2005;109:285–96. DOI: 10.1016/j.vetmic.2005.06.003
  5.   van Duijkeren E, Box ATA, Heck MEOC, Wannet WJB, Fluit AC. 
Methicillin-resistant staphylococci isolated from animals. Vet Mi-
crobiol. 2004;103:91–7. DOI: 10.1016/j.vetmic.2004.07.014
74  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 1, January 2010S. aureus Infections in Dogs
  6.   Wang JL, Chen SY, Wang JT, Wu GHM, Chiang WC, Hsueh PR, et 
al. Comparison of both clinical features and mortality risk associated 
with bacteremia due to community-acquired methicillin-resistant 
Staphylococcus aureus and methicillin-susceptible S. aureus. Clin 
Infect Dis. 2008;46:799–806. DOI: 10.1086/527389
  7.   Graffunder EM, Venezia RA. Risk factors associated with nosoco-
mial methicillin-resistant Staphylococcus aureus (MRSA) infec-
tion including previous use of antimicrobial drugs. J Antimicrob 
Chemother. 2002;49:999–1005. DOI: 10.1093/jac/dkf009
  8.   Wang FD, Chen YY, Chen TL, Liu CY. Risk factors and mortality in 
patients with nosocomial Staphylococcus aureus bacteremia. Am J 
Infect Control. 2008;36:118–22. DOI: 10.1016/j.ajic.2007.02.005
  9.   Shurland S, Zhan M, Bradham DD, Roghmann MC. Comparison of 
mortality risk associated with bacteremia due to methicillin-resistant 
and methicillin-susceptible Staphylococcus aureus. Infect Control 
Hosp Epidemiol. 2007;28:273–9. DOI: 10.1086/512627
10.   Melzer M, Eykyn SJ, Gransden WR, Chinn S. Is methicillin-resistant 
Staphylococcus aureus more virulent than methicillin-susceptible S. 
aureus? A comparative cohort study of British patients with noso-
comial infection and bacteremia. Clin Infect Dis. 2003;37:1453–60. 
DOI: 10.1086/379321
11.   Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karch-
mer AW, Carmeli Y. Comparison of mortality associated with me-
thicillin-resistant and methicillin-susceptible Staphylococcus aureus 
bacteremia: a meta-analysis. Clin Infect Dis. 2003;36:53–9. DOI: 
10.1086/345476
12.   Dancer SJ. The effect of antibiotics on methicillin-resistant Staphy-
lococcus aureus. J Antimicrob Chemother. 2008;61:246–53. DOI: 
10.1093/jac/dkm465
13.   Morris DO, Mauldin EA, O’Shea K, Shofer FS, Rankin SC. Clini-
cal, microbiological, and molecular characterization of methicillin-
resistant Staphylococcus aureus infections of cats. Am J Vet Res. 
2006;67:1421–5. DOI: 10.2460/ajvr.67.8.1421
14.   Weese JS, Lefebvre SL. Risk factors for methicillin-resistant Staph-
ylococcus aureus colonization in horses admitted to a veterinary 
teaching hospital. Can Vet J. 2007;48:921–6.
15.   Weese JS, Rousseau J, Willey BM, Archambault M, McGeer A, Low 
DE. Methicillin-resistant Staphylococcus aureus in horses at a vet-
erinary teaching hospital: frequency, characterization, and associa-
tion with clinical disease. J Vet Intern Med. 2006;20:182–6. DOI: 
10.1892/0891-6640(2006)20[182:MSAIHA]2.0.CO;2
16.   StataCorp. Exact logistic regression. In: Stata statistical software, 
release 10. College Station (TX): StataCorp LP; 2007. p. 423–39.
17.   Guardabassi L, Houser GA, Frank LA, Papich MG. Guidelines for 
antimicrobial use in dogs and cats. In: Guardabassi L, Jensen LB, 
Kruse H, editors. Guide to antimicrobial use in animals. Ames (IA): 
Blackwell; 2008. p. 183–206.
18.   Pedersen K, Pedersen K, Jensen H, Finster K, Jensen VF, Heuer OE. 
Occurrence of antimicrobial resistance in bacteria from diagnos-
tic samples from dogs. J Antimicrob Chemother. 2007;60:775–81. 
DOI: 10.1093/jac/dkm269
19.   Walker RD. Fluoroquinolones. In: Prescott JF, Baggot JD, Walker 
RD, editors. Antimicrobial therapy in veterinary medicine. 3rd ed. 
Ames (IA): Iowa State University Press; 2000. p. 315–38.
20.   Chaves F, Garcia-Martinez J, de Miguel S, Sanz F, Otero JR. Epi-
demiology and clonality of methicillin-resistant and methicillin-sus-
ceptible Staphylococcus aureus causing bacteremia in a tertiary-care 
hospital in Spain. Infect Control Hosp Epidemiol. 2005;26:150–6. 
DOI: 10.1086/502519
21.   Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. Fluo-
roquinolones and the risk for methicillin-resistant Staphylococcus 
aureus in hospitalized patients. Emerg Infect Dis. 2003;9:1415–22.
22.   Aldeyab MA, Monnet DL, Lopez-Lozano JM, Hughes CM, Scott 
MG, Kearney MP, et al. Modelling the impact of antibiotic use and 
infection control practices on the incidence of hospital-acquired 
methicillin-resistant  Staphylococcus aureus: a time-series analy-
sis. J Antimicrob Chemother. 2008;62:593–600. DOI: 10.1093/jac/
dkn198
23.   Bisognano C, Vaudaux P, Rohner P, Lew DP, Hooper DC. Induction 
of ﬁ  bronectin-binding proteins and increased adhesion of quinolo-
ne-resistant Staphylococcus aureus by subinhibitory levels of cip-
roﬂ  oxacin. Antimicrob Agents Chemother. 2000;44:1428–37. DOI: 
10.1128/AAC.44.6.1428-1437.2000
24.   Muller A, Mauny F, Talon D, Donnan PT, Harbarth S, Bertrand 
X. Effect of individual-and group-level antibiotic exposure on 
MRSA isolation: a multilevel analysis. J Antimicrob Chemother. 
2006;58:878–81. DOI: 10.1093/jac/dkl343
25.   Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-
resistant Staphylococcus aureus: a meta-analysis of prevalence and 
risk factors. Clin Infect Dis. 2003;36:131–9. DOI: 10.1086/345436
26.   Coello R, Glynn JR, Gaspar C, Picazo JJ, Fereres J. Risk factors for 
developing clinical infection with methicillin-resistant Staphylococ-
cus aureus (MRSA) amongst hospital patients initially only colo-
nized with MRSA. J Hosp Infect. 1997;37:39–46. DOI: 10.1016/
S0195-6701(97)90071-2
27.   Anderson MEC, Lefebvre SL, Rankin SC, Aceto H, Morley PS, 
Caron JP, et al. Retrospective multicentre study of methicillin-resis-
tant Staphylococcus aureus infections in 115 horses. Equine Vet J. 
2009;41:401–5. DOI: 10.2746/042516408X345134
Address for correspondence: Meredith C. Faires, Department of Population 
Medicine, Ontario Veterinary College, University of Guelph, Guelph, ON 
N1G 2W1, Canada; email: mfaires@uoguelph.ca
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 1, January 2010  75 